脈絡膜新生血管治療薬の世界市場（～2026年）

• 英文タイトル：Global Choroidal Neovascularization Drug Market Insights and Forecast to 2026

• レポートコード：MRC2-11QY00248
• 出版社/出版日：QYResearch / 2020年11月20日
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、154ページ
• 納品方法：Eメール（納期：2~3日）
• 産業分類：医療、製薬

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,170,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

当調査資料は脈絡膜新生血管治療薬のグローバル市場について調査・分析したレポートです。種類別（AVMOC-001、BB-3、BBT-007、DG-3、Entolimod、EWA-001、その他）市場規模、用途別（クリニック、病院、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。
・調査範囲
・エグゼクティブサマリー
・企業別脈絡膜新生血管治療薬の競争状況、市場シェア
・世界の脈絡膜新生血管治療薬市場：種類別市場規模 2015年-2020年（AVMOC-001、BB-3、BBT-007、DG-3、Entolimod、EWA-001、その他）
・世界の脈絡膜新生血管治療薬市場：種類別市場規模予測 2021年-2026年（AVMOC-001、BB-3、BBT-007、DG-3、Entolimod、EWA-001、その他）
・世界の脈絡膜新生血管治療薬市場：用途別市場規模 2015年-2020年（クリニック、病院、その他）
・世界の脈絡膜新生血管治療薬市場：用途別市場規模予測 2021年-2026年（クリニック、病院、その他）
・北米の脈絡膜新生血管治療薬市場分析：米国、カナダ
・ヨーロッパの脈絡膜新生血管治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの脈絡膜新生血管治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の脈絡膜新生血管治療薬市場分析：メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの脈絡膜新生血管治療薬市場分析：トルコ、サウジアラビア、UAE等
・企業情報（企業概要、製品概要、販売量、企業動向）
- 掲載企業（変更可能性あり）：Cellphire, Inc.、Chrysalis BioTherapeutics, Inc.、Cleveland BioLabs, Inc.、Cumberland Pharmaceuticals, Inc.、Diffusion Pharmaceuticals Inc.、Eli Lilly and Company、GNI Group Ltd.、Humanetics Corporation、INSYS Therapeutics, Inc.、Meabco A/S、Neumedicines Inc.、Onconova Therapeutics, Inc.、PharmaIN Corporation、Pluristem Therapeutics Inc.、ProCertus BioPharm Inc.、RDD Pharma Ltd.、RedHill Biopharma Ltd.、RxBio, Inc.、Soligenix, Inc.
・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論

Market Analysis and Insights: Global Choroidal Neovascularization Drug Market
The global Choroidal Neovascularization Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Choroidal Neovascularization Drug Scope and Market Size
Choroidal Neovascularization Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Choroidal Neovascularization Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Choroidal Neovascularization Drug market is segmented into
AVMOC-001
BB-3
BBT-007
DG-3
Entolimod
EWA-001
Others

Segment by Application, the Choroidal Neovascularization Drug market is segmented into
Clinic
Hospital
Others

Regional and Country-level Analysis
The Choroidal Neovascularization Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Choroidal Neovascularization Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Choroidal Neovascularization Drug Market Share Analysis
Choroidal Neovascularization Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Choroidal Neovascularization Drug business, the date to enter into the Choroidal Neovascularization Drug market, Choroidal Neovascularization Drug product introduction, recent developments, etc.

The major vendors covered:
Cellphire, Inc.
Chrysalis BioTherapeutics, Inc.
Cleveland BioLabs, Inc.
Cumberland Pharmaceuticals, Inc.
Diffusion Pharmaceuticals Inc.
Eli Lilly and Company
GNI Group Ltd.
Humanetics Corporation
INSYS Therapeutics, Inc.
Meabco A/S
Neumedicines Inc.
Onconova Therapeutics, Inc.
PharmaIN Corporation
Pluristem Therapeutics Inc.
ProCertus BioPharm Inc.
RDD Pharma Ltd.
RedHill Biopharma Ltd.
RxBio, Inc.
Soligenix, Inc.

レポート目次

1 Study Coverage
1.1 Choroidal Neovascularization Drug Product Introduction
1.2 Market Segments
1.3 Key Choroidal Neovascularization Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Choroidal Neovascularization Drug Market Size Growth Rate by Type
1.4.2 AVMOC-001
1.4.3 BB-3
1.4.4 BBT-007
1.4.5 DG-3
1.4.6 Entolimod
1.4.7 EWA-001
1.4.8 Others
1.5 Market by Application
1.5.1 Global Choroidal Neovascularization Drug Market Size Growth Rate by Application
1.5.2 Clinic
1.5.3 Hospital
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Choroidal Neovascularization Drug Market Size, Estimates and Forecasts
2.1.1 Global Choroidal Neovascularization Drug Revenue 2015-2026
2.1.2 Global Choroidal Neovascularization Drug Sales 2015-2026
2.2 Global Choroidal Neovascularization Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Choroidal Neovascularization Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Choroidal Neovascularization Drug Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Choroidal Neovascularization Drug Competitor Landscape by Players
3.1 Choroidal Neovascularization Drug Sales by Manufacturers
3.1.1 Choroidal Neovascularization Drug Sales by Manufacturers (2015-2020)
3.1.2 Choroidal Neovascularization Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Choroidal Neovascularization Drug Revenue by Manufacturers
3.2.1 Choroidal Neovascularization Drug Revenue by Manufacturers (2015-2020)
3.2.2 Choroidal Neovascularization Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Choroidal Neovascularization Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Choroidal Neovascularization Drug Revenue in 2019
3.2.5 Global Choroidal Neovascularization Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Choroidal Neovascularization Drug Price by Manufacturers
3.4 Choroidal Neovascularization Drug Manufacturing Base Distribution, Product Types
3.4.1 Choroidal Neovascularization Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Choroidal Neovascularization Drug Product Type
3.4.3 Date of International Manufacturers Enter into Choroidal Neovascularization Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Choroidal Neovascularization Drug Market Size by Type (2015-2020)
4.1.1 Global Choroidal Neovascularization Drug Sales by Type (2015-2020)
4.1.2 Global Choroidal Neovascularization Drug Revenue by Type (2015-2020)
4.1.3 Choroidal Neovascularization Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Choroidal Neovascularization Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Choroidal Neovascularization Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Choroidal Neovascularization Drug Revenue Forecast by Type (2021-2026)
4.2.3 Choroidal Neovascularization Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Choroidal Neovascularization Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
5.1 Global Choroidal Neovascularization Drug Market Size by Application (2015-2020)
5.1.1 Global Choroidal Neovascularization Drug Sales by Application (2015-2020)
5.1.2 Global Choroidal Neovascularization Drug Revenue by Application (2015-2020)
5.1.3 Choroidal Neovascularization Drug Price by Application (2015-2020)
5.2 Choroidal Neovascularization Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Choroidal Neovascularization Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Choroidal Neovascularization Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Choroidal Neovascularization Drug Price Forecast by Application (2021-2026)

6 North America
6.1 North America Choroidal Neovascularization Drug by Country
6.1.1 North America Choroidal Neovascularization Drug Sales by Country
6.1.2 North America Choroidal Neovascularization Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Choroidal Neovascularization Drug Market Facts & Figures by Type
6.3 North America Choroidal Neovascularization Drug Market Facts & Figures by Application

7 Europe
7.1 Europe Choroidal Neovascularization Drug by Country
7.1.1 Europe Choroidal Neovascularization Drug Sales by Country
7.1.2 Europe Choroidal Neovascularization Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Choroidal Neovascularization Drug Market Facts & Figures by Type
7.3 Europe Choroidal Neovascularization Drug Market Facts & Figures by Application

8 Asia Pacific
8.1 Asia Pacific Choroidal Neovascularization Drug by Region
8.1.1 Asia Pacific Choroidal Neovascularization Drug Sales by Region
8.1.2 Asia Pacific Choroidal Neovascularization Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Choroidal Neovascularization Drug Market Facts & Figures by Type
8.3 Asia Pacific Choroidal Neovascularization Drug Market Facts & Figures by Application

9 Latin America
9.1 Latin America Choroidal Neovascularization Drug by Country
9.1.1 Latin America Choroidal Neovascularization Drug Sales by Country
9.1.2 Latin America Choroidal Neovascularization Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Choroidal Neovascularization Drug Market Facts & Figures by Type
9.3 Central & South America Choroidal Neovascularization Drug Market Facts & Figures by Application

10 Middle East and Africa
10.1 Middle East and Africa Choroidal Neovascularization Drug by Country
10.1.1 Middle East and Africa Choroidal Neovascularization Drug Sales by Country
10.1.2 Middle East and Africa Choroidal Neovascularization Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Choroidal Neovascularization Drug Market Facts & Figures by Type
10.3 Middle East and Africa Choroidal Neovascularization Drug Market Facts & Figures by Application

11 Company Profiles
11.1 Cellphire, Inc.
11.1.1 Cellphire, Inc. Corporation Information
11.1.2 Cellphire, Inc. Description and Business Overview
11.1.3 Cellphire, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Cellphire, Inc. Choroidal Neovascularization Drug Products Offered
11.1.5 Cellphire, Inc. Related Developments
11.2 Chrysalis BioTherapeutics, Inc.
11.2.1 Chrysalis BioTherapeutics, Inc. Corporation Information
11.2.2 Chrysalis BioTherapeutics, Inc. Description and Business Overview
11.2.3 Chrysalis BioTherapeutics, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Products Offered
11.2.5 Chrysalis BioTherapeutics, Inc. Related Developments
11.3 Cleveland BioLabs, Inc.
11.3.1 Cleveland BioLabs, Inc. Corporation Information
11.3.2 Cleveland BioLabs, Inc. Description and Business Overview
11.3.3 Cleveland BioLabs, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Products Offered
11.3.5 Cleveland BioLabs, Inc. Related Developments
11.4 Cumberland Pharmaceuticals, Inc.
11.4.1 Cumberland Pharmaceuticals, Inc. Corporation Information
11.4.2 Cumberland Pharmaceuticals, Inc. Description and Business Overview
11.4.3 Cumberland Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Products Offered
11.4.5 Cumberland Pharmaceuticals, Inc. Related Developments
11.5 Diffusion Pharmaceuticals Inc.
11.5.1 Diffusion Pharmaceuticals Inc. Corporation Information
11.5.2 Diffusion Pharmaceuticals Inc. Description and Business Overview
11.5.3 Diffusion Pharmaceuticals Inc. Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Products Offered
11.5.5 Diffusion Pharmaceuticals Inc. Related Developments
11.6 Eli Lilly and Company
11.6.1 Eli Lilly and Company Corporation Information
11.6.2 Eli Lilly and Company Description and Business Overview
11.6.3 Eli Lilly and Company Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Eli Lilly and Company Choroidal Neovascularization Drug Products Offered
11.6.5 Eli Lilly and Company Related Developments
11.7 GNI Group Ltd.
11.7.1 GNI Group Ltd. Corporation Information
11.7.2 GNI Group Ltd. Description and Business Overview
11.7.3 GNI Group Ltd. Sales, Revenue and Gross Margin (2015-2020)
11.7.4 GNI Group Ltd. Choroidal Neovascularization Drug Products Offered
11.7.5 GNI Group Ltd. Related Developments
11.8 Humanetics Corporation
11.8.1 Humanetics Corporation Corporation Information
11.8.2 Humanetics Corporation Description and Business Overview
11.8.3 Humanetics Corporation Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Humanetics Corporation Choroidal Neovascularization Drug Products Offered
11.8.5 Humanetics Corporation Related Developments
11.9 INSYS Therapeutics, Inc.
11.9.1 INSYS Therapeutics, Inc. Corporation Information
11.9.2 INSYS Therapeutics, Inc. Description and Business Overview
11.9.3 INSYS Therapeutics, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.9.4 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Products Offered
11.9.5 INSYS Therapeutics, Inc. Related Developments
11.10 Meabco A/S
11.10.1 Meabco A/S Corporation Information
11.10.2 Meabco A/S Description and Business Overview
11.10.3 Meabco A/S Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Meabco A/S Choroidal Neovascularization Drug Products Offered
11.10.5 Meabco A/S Related Developments
11.1 Cellphire, Inc.
11.1.1 Cellphire, Inc. Corporation Information
11.1.2 Cellphire, Inc. Description and Business Overview
11.1.3 Cellphire, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Cellphire, Inc. Choroidal Neovascularization Drug Products Offered
11.1.5 Cellphire, Inc. Related Developments
11.12 Onconova Therapeutics, Inc.
11.12.1 Onconova Therapeutics, Inc. Corporation Information
11.12.2 Onconova Therapeutics, Inc. Description and Business Overview
11.12.3 Onconova Therapeutics, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Onconova Therapeutics, Inc. Products Offered
11.12.5 Onconova Therapeutics, Inc. Related Developments
11.13 PharmaIN Corporation
11.13.1 PharmaIN Corporation Corporation Information
11.13.2 PharmaIN Corporation Description and Business Overview
11.13.3 PharmaIN Corporation Sales, Revenue and Gross Margin (2015-2020)
11.13.4 PharmaIN Corporation Products Offered
11.13.5 PharmaIN Corporation Related Developments
11.14 Pluristem Therapeutics Inc.
11.14.1 Pluristem Therapeutics Inc. Corporation Information
11.14.2 Pluristem Therapeutics Inc. Description and Business Overview
11.14.3 Pluristem Therapeutics Inc. Sales, Revenue and Gross Margin (2015-2020)
11.14.4 Pluristem Therapeutics Inc. Products Offered
11.14.5 Pluristem Therapeutics Inc. Related Developments
11.15 ProCertus BioPharm Inc.
11.15.1 ProCertus BioPharm Inc. Corporation Information
11.15.2 ProCertus BioPharm Inc. Description and Business Overview
11.15.3 ProCertus BioPharm Inc. Sales, Revenue and Gross Margin (2015-2020)
11.15.4 ProCertus BioPharm Inc. Products Offered
11.15.5 ProCertus BioPharm Inc. Related Developments
11.16 RDD Pharma Ltd.
11.16.1 RDD Pharma Ltd. Corporation Information
11.16.2 RDD Pharma Ltd. Description and Business Overview
11.16.3 RDD Pharma Ltd. Sales, Revenue and Gross Margin (2015-2020)
11.16.4 RDD Pharma Ltd. Products Offered
11.16.5 RDD Pharma Ltd. Related Developments
11.17 RedHill Biopharma Ltd.
11.17.1 RedHill Biopharma Ltd. Corporation Information
11.17.2 RedHill Biopharma Ltd. Description and Business Overview
11.17.3 RedHill Biopharma Ltd. Sales, Revenue and Gross Margin (2015-2020)
11.17.4 RedHill Biopharma Ltd. Products Offered
11.17.5 RedHill Biopharma Ltd. Related Developments
11.18 RxBio, Inc.
11.18.1 RxBio, Inc. Corporation Information
11.18.2 RxBio, Inc. Description and Business Overview
11.18.3 RxBio, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.18.4 RxBio, Inc. Products Offered
11.18.5 RxBio, Inc. Related Developments
11.19 Soligenix, Inc.
11.19.1 Soligenix, Inc. Corporation Information
11.19.2 Soligenix, Inc. Description and Business Overview
11.19.3 Soligenix, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.19.4 Soligenix, Inc. Products Offered
11.19.5 Soligenix, Inc. Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Choroidal Neovascularization Drug Market Estimates and Projections by Region
12.1.1 Global Choroidal Neovascularization Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Choroidal Neovascularization Drug Revenue Forecast by Regions 2021-2026
12.2 North America Choroidal Neovascularization Drug Market Size Forecast (2021-2026)
12.2.1 North America: Choroidal Neovascularization Drug Sales Forecast (2021-2026)
12.2.2 North America: Choroidal Neovascularization Drug Revenue Forecast (2021-2026)
12.2.3 North America: Choroidal Neovascularization Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Choroidal Neovascularization Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Choroidal Neovascularization Drug Sales Forecast (2021-2026)
12.3.2 Europe: Choroidal Neovascularization Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Choroidal Neovascularization Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Choroidal Neovascularization Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Choroidal Neovascularization Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Choroidal Neovascularization Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Choroidal Neovascularization Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Choroidal Neovascularization Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Choroidal Neovascularization Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Choroidal Neovascularization Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Choroidal Neovascularization Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Choroidal Neovascularization Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Choroidal Neovascularization Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Choroidal Neovascularization Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Choroidal Neovascularization Drug Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Choroidal Neovascularization Drug Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Choroidal Neovascularization Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

List of Tables
Table 1. Choroidal Neovascularization Drug Market Segments
Table 2. Ranking of Global Top Choroidal Neovascularization Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Choroidal Neovascularization Drug Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of AVMOC-001
Table 5. Major Manufacturers of BB-3
Table 6. Major Manufacturers of BBT-007
Table 7. Major Manufacturers of DG-3
Table 8. Major Manufacturers of Entolimod
Table 9. Major Manufacturers of EWA-001
Table 10. Major Manufacturers of Others
Table 11. Global Choroidal Neovascularization Drug Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 12. Global Choroidal Neovascularization Drug Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 13. Global Choroidal Neovascularization Drug Sales by Regions 2015-2020 (K Pcs)
Table 14. Global Choroidal Neovascularization Drug Sales Market Share by Regions (2015-2020)
Table 15. Global Choroidal Neovascularization Drug Revenue by Regions 2015-2020 (US$ Million)
Table 16. Global Choroidal Neovascularization Drug Sales by Manufacturers (2015-2020) (K Pcs)
Table 17. Global Choroidal Neovascularization Drug Sales Share by Manufacturers (2015-2020)
Table 18. Global Choroidal Neovascularization Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 19. Global Choroidal Neovascularization Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Choroidal Neovascularization Drug as of 2019)
Table 20. Choroidal Neovascularization Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 21. Choroidal Neovascularization Drug Revenue Share by Manufacturers (2015-2020)
Table 22. Key Manufacturers Choroidal Neovascularization Drug Price (2015-2020) (USD/Pcs)
Table 23. Choroidal Neovascularization Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 24. Manufacturers Choroidal Neovascularization Drug Product Type
Table 25. Date of International Manufacturers Enter into Choroidal Neovascularization Drug Market
Table 26. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 27. Global Choroidal Neovascularization Drug Sales by Type (2015-2020) (K Pcs)
Table 28. Global Choroidal Neovascularization Drug Sales Share by Type (2015-2020)
Table 29. Global Choroidal Neovascularization Drug Revenue by Type (2015-2020) (US$ Million)
Table 30. Global Choroidal Neovascularization Drug Revenue Share by Type (2015-2020)
Table 31. Choroidal Neovascularization Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 32. Global Choroidal Neovascularization Drug Sales by Application (2015-2020) (K Pcs)
Table 33. Global Choroidal Neovascularization Drug Sales Share by Application (2015-2020)
Table 34. North America Choroidal Neovascularization Drug Sales by Country (2015-2020) (K Pcs)
Table 35. North America Choroidal Neovascularization Drug Sales Market Share by Country (2015-2020)
Table 36. North America Choroidal Neovascularization Drug Revenue by Country (2015-2020) (US$ Million)
Table 37. North America Choroidal Neovascularization Drug Revenue Market Share by Country (2015-2020)
Table 38. North America Choroidal Neovascularization Drug Sales by Type (2015-2020) (K Pcs)
Table 39. North America Choroidal Neovascularization Drug Sales Market Share by Type (2015-2020)
Table 40. North America Choroidal Neovascularization Drug Sales by Application (2015-2020) (K Pcs)
Table 41. North America Choroidal Neovascularization Drug Sales Market Share by Application (2015-2020)
Table 42. Europe Choroidal Neovascularization Drug Sales by Country (2015-2020) (K Pcs)
Table 43. Europe Choroidal Neovascularization Drug Sales Market Share by Country (2015-2020)
Table 44. Europe Choroidal Neovascularization Drug Revenue by Country (2015-2020) (US$ Million)
Table 45. Europe Choroidal Neovascularization Drug Revenue Market Share by Country (2015-2020)
Table 46. Europe Choroidal Neovascularization Drug Sales by Type (2015-2020) (K Pcs)
Table 47. Europe Choroidal Neovascularization Drug Sales Market Share by Type (2015-2020)
Table 48. Europe Choroidal Neovascularization Drug Sales by Application (2015-2020) (K Pcs)
Table 49. Europe Choroidal Neovascularization Drug Sales Market Share by Application (2015-2020)
Table 50. Asia Pacific Choroidal Neovascularization Drug Sales by Region (2015-2020) (K Pcs)
Table 51. Asia Pacific Choroidal Neovascularization Drug Sales Market Share by Region (2015-2020)
Table 52. Asia Pacific Choroidal Neovascularization Drug Revenue by Region (2015-2020) (US$ Million)
Table 53. Asia Pacific Choroidal Neovascularization Drug Revenue Market Share by Region (2015-2020)
Table 54. Asia Pacific Choroidal Neovascularization Drug Sales by Type (2015-2020) (K Pcs)
Table 55. Asia Pacific Choroidal Neovascularization Drug Sales Market Share by Type (2015-2020)
Table 56. Asia Pacific Choroidal Neovascularization Drug Sales by Application (2015-2020) (K Pcs)
Table 57. Asia Pacific Choroidal Neovascularization Drug Sales Market Share by Application (2015-2020)
Table 58. Latin America Choroidal Neovascularization Drug Sales by Country (2015-2020) (K Pcs)
Table 59. Latin America Choroidal Neovascularization Drug Sales Market Share by Country (2015-2020)
Table 60. Latin Americaa Choroidal Neovascularization Drug Revenue by Country (2015-2020) (US$ Million)
Table 61. Latin America Choroidal Neovascularization Drug Revenue Market Share by Country (2015-2020)
Table 62. Latin America Choroidal Neovascularization Drug Sales by Type (2015-2020) (K Pcs)
Table 63. Latin America Choroidal Neovascularization Drug Sales Market Share by Type (2015-2020)
Table 64. Latin America Choroidal Neovascularization Drug Sales by Application (2015-2020) (K Pcs)
Table 65. Latin America Choroidal Neovascularization Drug Sales Market Share by Application (2015-2020)
Table 66. Middle East and Africa Choroidal Neovascularization Drug Sales by Country (2015-2020) (K Pcs)
Table 67. Middle East and Africa Choroidal Neovascularization Drug Sales Market Share by Country (2015-2020)
Table 68. Middle East and Africa Choroidal Neovascularization Drug Revenue by Country (2015-2020) (US$ Million)
Table 69. Middle East and Africa Choroidal Neovascularization Drug Revenue Market Share by Country (2015-2020)
Table 70. Middle East and Africa Choroidal Neovascularization Drug Sales by Type (2015-2020) (K Pcs)
Table 71. Middle East and Africa Choroidal Neovascularization Drug Sales Market Share by Type (2015-2020)
Table 72. Middle East and Africa Choroidal Neovascularization Drug Sales by Application (2015-2020) (K Pcs)
Table 73. Middle East and Africa Choroidal Neovascularization Drug Sales Market Share by Application (2015-2020)
Table 74. Cellphire, Inc. Corporation Information
Table 75. Cellphire, Inc. Description and Major Businesses
Table 76. Cellphire, Inc. Choroidal Neovascularization Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 77. Cellphire, Inc. Product
Table 78. Cellphire, Inc. Recent Development
Table 79. Chrysalis BioTherapeutics, Inc. Corporation Information
Table 80. Chrysalis BioTherapeutics, Inc. Description and Major Businesses
Table 81. Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 82. Chrysalis BioTherapeutics, Inc. Product
Table 83. Chrysalis BioTherapeutics, Inc. Recent Development
Table 84. Cleveland BioLabs, Inc. Corporation Information
Table 85. Cleveland BioLabs, Inc. Description and Major Businesses
Table 86. Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 87. Cleveland BioLabs, Inc. Product
Table 88. Cleveland BioLabs, Inc. Recent Development
Table 89. Cumberland Pharmaceuticals, Inc. Corporation Information
Table 90. Cumberland Pharmaceuticals, Inc. Description and Major Businesses
Table 91. Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 92. Cumberland Pharmaceuticals, Inc. Product
Table 93. Cumberland Pharmaceuticals, Inc. Recent Development
Table 94. Diffusion Pharmaceuticals Inc. Corporation Information
Table 95. Diffusion Pharmaceuticals Inc. Description and Major Businesses
Table 96. Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 97. Diffusion Pharmaceuticals Inc. Product
Table 98. Diffusion Pharmaceuticals Inc. Recent Development
Table 99. Eli Lilly and Company Corporation Information
Table 100. Eli Lilly and Company Description and Major Businesses
Table 101. Eli Lilly and Company Choroidal Neovascularization Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 102. Eli Lilly and Company Product
Table 103. Eli Lilly and Company Recent Development
Table 104. GNI Group Ltd. Corporation Information
Table 105. GNI Group Ltd. Description and Major Businesses
Table 106. GNI Group Ltd. Choroidal Neovascularization Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 107. GNI Group Ltd. Product
Table 108. GNI Group Ltd. Recent Development
Table 109. Humanetics Corporation Corporation Information
Table 110. Humanetics Corporation Description and Major Businesses
Table 111. Humanetics Corporation Choroidal Neovascularization Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 112. Humanetics Corporation Product
Table 113. Humanetics Corporation Recent Development
Table 114. INSYS Therapeutics, Inc. Corporation Information
Table 115. INSYS Therapeutics, Inc. Description and Major Businesses
Table 116. INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 117. INSYS Therapeutics, Inc. Product
Table 118. INSYS Therapeutics, Inc. Recent Development
Table 119. Meabco A/S Corporation Information
Table 120. Meabco A/S Description and Major Businesses
Table 121. Meabco A/S Choroidal Neovascularization Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 122. Meabco A/S Product
Table 123. Meabco A/S Recent Development
Table 124. Neumedicines Inc. Corporation Information
Table 125. Neumedicines Inc. Description and Major Businesses
Table 126. Neumedicines Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 127. Neumedicines Inc. Product
Table 128. Neumedicines Inc. Recent Development
Table 129. Onconova Therapeutics, Inc. Corporation Information
Table 130. Onconova Therapeutics, Inc. Description and Major Businesses
Table 131. Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 132. Onconova Therapeutics, Inc. Product
Table 133. Onconova Therapeutics, Inc. Recent Development
Table 134. PharmaIN Corporation Corporation Information
Table 135. PharmaIN Corporation Description and Major Businesses
Table 136. PharmaIN Corporation Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 137. PharmaIN Corporation Product
Table 138. PharmaIN Corporation Recent Development
Table 139. Pluristem Therapeutics Inc. Corporation Information
Table 140. Pluristem Therapeutics Inc. Description and Major Businesses
Table 141. Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 142. Pluristem Therapeutics Inc. Product
Table 143. Pluristem Therapeutics Inc. Recent Development
Table 144. ProCertus BioPharm Inc. Corporation Information
Table 145. ProCertus BioPharm Inc. Description and Major Businesses
Table 146. ProCertus BioPharm Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 147. ProCertus BioPharm Inc. Product
Table 148. ProCertus BioPharm Inc. Recent Development
Table 149. RDD Pharma Ltd. Corporation Information
Table 150. RDD Pharma Ltd. Description and Major Businesses
Table 151. RDD Pharma Ltd. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 152. RDD Pharma Ltd. Product
Table 153. RDD Pharma Ltd. Recent Development
Table 154. RedHill Biopharma Ltd. Corporation Information
Table 155. RedHill Biopharma Ltd. Description and Major Businesses
Table 156. RedHill Biopharma Ltd. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 157. RedHill Biopharma Ltd. Product
Table 158. RedHill Biopharma Ltd. Recent Development
Table 159. RxBio, Inc. Corporation Information
Table 160. RxBio, Inc. Description and Major Businesses
Table 161. RxBio, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 162. RxBio, Inc. Product
Table 163. RxBio, Inc. Recent Development
Table 164. Soligenix, Inc. Corporation Information
Table 165. Soligenix, Inc. Description and Major Businesses
Table 166. Soligenix, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 167. Soligenix, Inc. Product
Table 168. Soligenix, Inc. Recent Development
Table 169. Global Choroidal Neovascularization Drug Sales Forecast by Regions (2021-2026) (K Pcs)
Table 170. Global Choroidal Neovascularization Drug Sales Market Share Forecast by Regions (2021-2026)
Table 171. Global Choroidal Neovascularization Drug Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 172. Global Choroidal Neovascularization Drug Revenue Market Share Forecast by Regions (2021-2026)
Table 173. North America: Choroidal Neovascularization Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 174. North America: Choroidal Neovascularization Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 175. Europe: Choroidal Neovascularization Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 176. Europe: Choroidal Neovascularization Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 177. Asia Pacific: Choroidal Neovascularization Drug Sales Forecast by Region (2021-2026) (K Pcs)
Table 178. Asia Pacific: Choroidal Neovascularization Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 179. Latin America: Choroidal Neovascularization Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 180. Latin America: Choroidal Neovascularization Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 181. Middle East and Africa: Choroidal Neovascularization Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 182. Middle East and Africa: Choroidal Neovascularization Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 183. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 184. Key Challenges
Table 185. Market Risks
Table 186. Main Points Interviewed from Key Choroidal Neovascularization Drug Players
Table 187. Choroidal Neovascularization Drug Customers List
Table 188. Choroidal Neovascularization Drug Distributors List
Table 189. Research Programs/Design for This Report
Table 190. Key Data Information from Secondary Sources
Table 191. Key Data Information from Primary Sources
List of Figures
Figure 1. Choroidal Neovascularization Drug Product Picture
Figure 2. Global Choroidal Neovascularization Drug Sales Market Share by Type in 2020 & 2026
Figure 3. AVMOC-001 Product Picture
Figure 4. BB-3 Product Picture
Figure 5. BBT-007 Product Picture
Figure 6. DG-3 Product Picture
Figure 7. Entolimod Product Picture
Figure 8. EWA-001 Product Picture
Figure 9. Others Product Picture
Figure 10. Global Choroidal Neovascularization Drug Sales Market Share by Application in 2020 & 2026
Figure 11. Clinic
Figure 12. Hospital
Figure 13. Others
Figure 14. Choroidal Neovascularization Drug Report Years Considered
Figure 15. Global Choroidal Neovascularization Drug Market Size 2015-2026 (US$ Million)
Figure 16. Global Choroidal Neovascularization Drug Sales 2015-2026 (K Pcs)
Figure 17. Global Choroidal Neovascularization Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 18. Global Choroidal Neovascularization Drug Sales Market Share by Region (2015-2020)
Figure 19. Global Choroidal Neovascularization Drug Sales Market Share by Region in 2019
Figure 20. Global Choroidal Neovascularization Drug Revenue Market Share by Region (2015-2020)
Figure 21. Global Choroidal Neovascularization Drug Revenue Market Share by Region in 2019
Figure 22. Global Choroidal Neovascularization Drug Sales Share by Manufacturer in 2019
Figure 23. The Top 10 and 5 Players Market Share by Choroidal Neovascularization Drug Revenue in 2019
Figure 24. Choroidal Neovascularization Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 25. Global Choroidal Neovascularization Drug Sales Market Share by Type (2015-2020)
Figure 26. Global Choroidal Neovascularization Drug Sales Market Share by Type in 2019
Figure 27. Global Choroidal Neovascularization Drug Revenue Market Share by Type (2015-2020)
Figure 28. Global Choroidal Neovascularization Drug Revenue Market Share by Type in 2019
Figure 29. Global Choroidal Neovascularization Drug Market Share by Price Range (2015-2020)
Figure 30. Global Choroidal Neovascularization Drug Sales Market Share by Application (2015-2020)
Figure 31. Global Choroidal Neovascularization Drug Sales Market Share by Application in 2019
Figure 32. Global Choroidal Neovascularization Drug Revenue Market Share by Application (2015-2020)
Figure 33. Global Choroidal Neovascularization Drug Revenue Market Share by Application in 2019
Figure 34. North America Choroidal Neovascularization Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 35. North America Choroidal Neovascularization Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 36. North America Choroidal Neovascularization Drug Sales Market Share by Country in 2019
Figure 37. North America Choroidal Neovascularization Drug Revenue Market Share by Country in 2019
Figure 38. U.S. Choroidal Neovascularization Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 39. U.S. Choroidal Neovascularization Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 40. Canada Choroidal Neovascularization Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 41. Canada Choroidal Neovascularization Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 42. North America Choroidal Neovascularization Drug Market Share by Type in 2019
Figure 43. North America Choroidal Neovascularization Drug Market Share by Application in 2019
Figure 44. Europe Choroidal Neovascularization Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 45. Europe Choroidal Neovascularization Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 46. Europe Choroidal Neovascularization Drug Sales Market Share by Country in 2019
Figure 47. Europe Choroidal Neovascularization Drug Revenue Market Share by Country in 2019
Figure 48. Germany Choroidal Neovascularization Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 49. Germany Choroidal Neovascularization Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. France Choroidal Neovascularization Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 51. France Choroidal Neovascularization Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. U.K. Choroidal Neovascularization Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 53. U.K. Choroidal Neovascularization Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Italy Choroidal Neovascularization Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 55. Italy Choroidal Neovascularization Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Russia Choroidal Neovascularization Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 57. Russia Choroidal Neovascularization Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 58. Europe Choroidal Neovascularization Drug Market Share by Type in 2019
Figure 59. Europe Choroidal Neovascularization Drug Market Share by Application in 2019
Figure 60. Asia Pacific Choroidal Neovascularization Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 61. Asia Pacific Choroidal Neovascularization Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 62. Asia Pacific Choroidal Neovascularization Drug Sales Market Share by Region in 2019
Figure 63. Asia Pacific Choroidal Neovascularization Drug Revenue Market Share by Region in 2019
Figure 64. China Choroidal Neovascularization Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 65. China Choroidal Neovascularization Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. Japan Choroidal Neovascularization Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 67. Japan Choroidal Neovascularization Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. South Korea Choroidal Neovascularization Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 69. South Korea Choroidal Neovascularization Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. India Choroidal Neovascularization Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 71. India Choroidal Neovascularization Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Australia Choroidal Neovascularization Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 73. Australia Choroidal Neovascularization Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Taiwan Choroidal Neovascularization Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 75. Taiwan Choroidal Neovascularization Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Indonesia Choroidal Neovascularization Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 77. Indonesia Choroidal Neovascularization Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Thailand Choroidal Neovascularization Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 79. Thailand Choroidal Neovascularization Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Malaysia Choroidal Neovascularization Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 81. Malaysia Choroidal Neovascularization Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Philippines Choroidal Neovascularization Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 83. Philippines Choroidal Neovascularization Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 84. Vietnam Choroidal Neovascularization Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 85. Vietnam Choroidal Neovascularization Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 86. Asia Pacific Choroidal Neovascularization Drug Market Share by Type in 2019
Figure 87. Asia Pacific Choroidal Neovascularization Drug Market Share by Application in 2019
Figure 88. Latin America Choroidal Neovascularization Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 89. Latin America Choroidal Neovascularization Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 90. Latin America Choroidal Neovascularization Drug Sales Market Share by Country in 2019
Figure 91. Latin America Choroidal Neovascularization Drug Revenue Market Share by Country in 2019
Figure 92. Mexico Choroidal Neovascularization Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 93. Mexico Choroidal Neovascularization Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Brazil Choroidal Neovascularization Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 95. Brazil Choroidal Neovascularization Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 96. Argentina Choroidal Neovascularization Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 97. Argentina Choroidal Neovascularization Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 98. Latin America Choroidal Neovascularization Drug Market Share by Type in 2019
Figure 99. Latin America Choroidal Neovascularization Drug Market Share by Application in 2019
Figure 100. Middle East and Africa Choroidal Neovascularization Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 101. Middle East and Africa Choroidal Neovascularization Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 102. Middle East and Africa Choroidal Neovascularization Drug Sales Market Share by Country in 2019
Figure 103. Middle East and Africa Choroidal Neovascularization Drug Revenue Market Share by Country in 2019
Figure 104. Turkey Choroidal Neovascularization Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 105. Turkey Choroidal Neovascularization Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. Saudi Arabia Choroidal Neovascularization Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 107. Saudi Arabia Choroidal Neovascularization Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 108. U.A.E Choroidal Neovascularization Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 109. U.A.E Choroidal Neovascularization Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 110. Middle East and Africa Choroidal Neovascularization Drug Market Share by Type in 2019
Figure 111. Middle East and Africa Choroidal Neovascularization Drug Market Share by Application in 2019
Figure 112. North America Choroidal Neovascularization Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 113. North America Choroidal Neovascularization Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Europe Choroidal Neovascularization Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 115. Europe Choroidal Neovascularization Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Asia Pacific Choroidal Neovascularization Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 117. Asia Pacific Choroidal Neovascularization Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Latin America Choroidal Neovascularization Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 119. Latin America Choroidal Neovascularization Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 120. Middle East and Africa Choroidal Neovascularization Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 121. Middle East and Africa Choroidal Neovascularization Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 122. Porter's Five Forces Analysis
Figure 123. Channels of Distribution
Figure 124. Distributors Profiles
Figure 125. Bottom-up and Top-down Approaches for This Report
Figure 126. Data Triangulation
Figure 127. Key Executives Interviewed

以下、関連資料のご紹介

小売薬の世界市場（～2026年）

Global Retail Drug Market Size, Status and Forecast 2020-2026
MRC2-11QY04497 2020年11月20日 99Pages
当調査資料は小売薬のグローバル市場について調査・分析したレポートです。種類別（ジェネリック医薬品、OTC医薬品、その他）市場規模、用途別（病院、クリニック、家庭用）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オース...

創薬の世界市場（～2026年）

Global Drug Discovery Market Size, Status and Forecast 2020-2026
MRC2-11QY11717 2020年11月25日 95Pages
当調査資料は創薬のグローバル市場について調査・分析したレポートです。種類別（小分子薬、生物製剤）市場規模、用途別（研究所、製薬会社、バイオテクノロジー会社）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア...

創薬アウトソーシングの世界市場（～2026年）

Global Drug Discovery Outsourcing Market Size, Status and Forecast 2020-2026
MRC2-11QY11718 2020年11月25日 90Pages
当調査資料は創薬アウトソーシングのグローバル市場について調査・分析したレポートです。種類別（小分子、生物製剤）市場規模、用途別（病院・クリニック、臨床検査室、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オー...

ドラッグデリバリーにおけるナノテクノロジーの世界市場（～2026年）

Global Nanotechnology in Drug Delivery Market Size, Status and Forecast 2020-2026
MRC2-11QY03902 2020年11月20日 94Pages
当調査資料はドラッグデリバリーにおけるナノテクノロジーのグローバル市場について調査・分析したレポートです。種類別（ターゲットデリバリー、薬剤包装）市場規模、用途別（がん、腫瘍、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、...

ドラッグリポジショニングの世界市場（～2026年）

Global Drug Repurposing Market Size, Status and Forecast 2020-2026
MRC2-11QY11721 2020年11月25日 93Pages
当調査資料はドラッグリポジショニングのグローバル市場について調査・分析したレポートです。種類別（腫瘍、中枢神経系疾患、神経変性疾患、その他）市場規模、用途別（病院、外来手術センター、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、...

乱用薬物検査サービスの世界市場（～2026年）

Global Drug of Abuse Testing Services Market Size, Status and Forecast 2020-2026
MRC2-11QY11720 2020年11月25日 93Pages
当調査資料は乱用薬物検査サービスのグローバル市場について調査・分析したレポートです。種類別（アルコール、大麻、コカイン、オピオイド、アンフェタミン、LSD、その他）市場規模、用途別（病院、実験室、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、...

深部静脈血栓症（DVT）治療薬の世界市場（～2026年）

Global Deep Vein Thrombosis (DVT) Drug Market Size, Status and Forecast 2020-2026
MRC2-11QY11584 2020年11月25日 97Pages
当調査資料は深部静脈血栓症（DVT）治療薬のグローバル市場について調査・分析したレポートです。種類別（抗凝血剤、組織プラスミノーゲン活性化因子、その他薬剤）市場規模、用途別（病院、クリニック、ドラッグストア）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシ...

高度ドラッグデリバリーシステムの世界市場（～2026年）

Global Advanced Drug Delivery Systems Market Size, Status and Forecast 2020-2026
MRC2-11QY13587 2020年11月30日 92Pages
当調査資料は高度ドラッグデリバリーシステムのグローバル市場について調査・分析したレポートです。種類別（経口ドラッグデリバリー、肺ドラッグデリバリー、経皮ドラッグデリバリー、非経口ドラッグデリバリー）市場規模、用途別（病院、専門クリニック、臨床研究開発センター）市場規模、地域別（北米、米国、カナダ、ヨ...

糖尿病性黄斑浮腫治療薬の世界市場（～2026年）

Global Diabetic Macular Edema Drug Market Size, Status and Forecast 2020-2026
MRC2-11QY11631 2020年11月25日 99Pages
当調査資料は糖尿病性黄斑浮腫治療薬のグローバル市場について調査・分析したレポートです。種類別（硝子体内注射、硝子体内インプラント）市場規模、用途別（抗VEGF、コルチコステロイド、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中...

NSAID治療薬の世界市場（～2026年）

Global NSAIDs Drug Market Size, Status and Forecast 2020-2026
MRC2-11QY04016 2020年11月20日 133Pages
当調査資料はNSAID治療薬のグローバル市場について調査・分析したレポートです。種類別（イブプロフェン、ナプロキセン）市場規模、用途別（病院、診療所、ドラッグストア）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オー...

小売薬の世界市場（～2026年） A drug is any substance (other than food that provides nutritional support) that, when inhaled, injected, smoked, consumed, absorbed via a patch on the skin, or dissolved under the tongue causes a temporary physiological (and often psychological) change in the body. Increasing industry share of Asia…
大麻薬の世界市場（～2026年） Drugs with chemicals taken directly from the marijuana plant，or with synthetic versions of chemicals naturally found in marijuana. Market Analysis and Insights: Global Cannabis Drug Market The global Cannabis Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020,…
ドラッグリポジショニングの世界市場（～2026年） Drug repurposing or re-profiling has been the hallmark to bring strong business growth and the trend is being followed by majority of the pharmaceutical and biopharmaceutical companies. Among all biologics approved in the U.S. during 2007-2009, 30-40% of them were the drugs repurposed or repositione…
乱用薬物検査サービスの世界市場（～2026年） Drug of Abuse Testing Services is the use of testing services to avoid the negative effects of drug abuse, to reduce the accidents. In addition to rise in number of substance abusers and increase in number of government initiatives to avoid ill effects of substance abuse at workplace & reduce number…
創薬の世界市場（～2026年） Drug discovery is the process by which new candidate medications are discovered. The pharmaceutical and biotech companies are increasing their collaboration with contract development and manufacturing organizations, thus playing a crucial role in the development and innovation of new drugs. Other fa…